Acadian Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Acadian Asset Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$309K	Buy	+14,837	New	+$334K	﹤0.01%	1477
2025 Q4	–	Sell	-4,463	Closed	-$133K	–	2093
2025 Q3	$133K	Buy	+4,463	New	+$134K	﹤0.01%	1465
2024 Q4	–	Sell	-1,692	Closed	-$93K	–	2061
2024 Q3	$93K	Buy	+1,692	New	+$86.2K	﹤0.01%	1614
2023 Q3	–	Sell	-1,940	Closed	-$88K	–	1804
2023 Q2	$88K	Sell	1,940 -8,463	-81%	-$393K	﹤0.01%	1429
2023 Q1	$416K	Buy	10,403 +5,437	+109%	+$233K	﹤0.01%	1097
2022 Q4	$228K	Buy	4,966 +4,196	+545%	+$165K	﹤0.01%	1249
2022 Q3	$31K	Buy	+770	New	+$39.6K	﹤0.01%	1555
2021 Q3	–	Sell	-424	Closed	-$40K	–	1962
2021 Q2	$40K	Buy	+424	New	+$44.2K	﹤0.01%	1835
2021 Q1	–	Sell	-364	Closed	-$50K	–	2279
2020 Q4	$50K	Buy	+364	New	+$43.2K	﹤0.01%	1933

Other funds holding RARE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Acadian Asset Management's RARE Position: Q1 2026 in Review

Acadian Asset Management opened a new position in Ultragenyx Pharmaceutical (RARE) in Q1 2026: 14,837 shares worth $309K. The stake represents ﹤0.01% of the portfolio and ranks #1477 among its holdings. This is a return to the name: Acadian Asset Management previously reported a position in RARE as recently as Q3 2025.

Acadian Asset Management first reported a position in RARE in Q4 2020 and has held it in 9 quarters since. The position peaked at $416K in Q1 2023. 296 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

Acadian Asset Management held 14,837 shares of Ultragenyx Pharmaceutical worth $309K as of Q1 2026.
Ultragenyx Pharmaceutical was a new Acadian Asset Management position in Q1 2026.
Ultragenyx Pharmaceutical made up ﹤0.01% of Acadian Asset Management's portfolio in Q1 2026, its #1477 holding.
Acadian Asset Management first reported a position in Ultragenyx Pharmaceutical in Q4 2020 and has held it in 9 quarters since.
Acadian Asset Management's Ultragenyx Pharmaceutical position peaked at $416K in Q1 2023.
296 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.